Progress, consolidation, and prospects for a new cycle.

Abstract

Dear readers and collaborators,

We conclude Volume 7, Number 5 of the Brazilian Journal of Health and Pharmacy (BJHP) celebrating a year of important achievements for the journal and for the scientific community that follows us. In 2025, we made significant progress in the professionalization of editorial processes, with the implementation of a computerized system for manuscript submission and management, increasing the transparency and efficiency of peer review. Unprecedentedly, we published five issues throughout the year, including international contributions, reaffirming the consolidation of BJHP in the national scene and expanding its dialogue with researchers from other countries.

This latest issue brings together four studies that reflect the thematic diversity and growing relevance of Pharmacy and Health research in Brazil and Latin America. The first article presents an overview of the most requested compounded formulations in a compounding pharmacy in Minas Gerais, highlighting therapeutic preferences, motivations for use, and perceptions of efficacy among users—essential elements for understanding contemporary compounding practice and its interfaces with patient safety. The second study, conducted in a Mexican tertiary center, describes an extensive clinical, demographic, and histopathological profile of adverse skin reactions to medications over nine years, highlighting the diagnostic complexity of these conditions and reinforcing the need for robust pharmacovigilance strategies. In the field of chronic disease care, the third article analyzes the profile of patients using acetylsalicylic acid for the prevention of cardiovascular events in a municipality in Minas Gerais. The findings reveal discrepancies between clinical practice and the most recent recommendations, pointing to the urgency of revisiting prescribing and monitoring criteria for these individuals. The fourth manuscript investigates the susceptibility of uropathogenic Escherichia coli to first-line antimicrobials in the treatment of urinary tract infections, providing updated evidence on bacterial resistance and reinforcing the strategic role of clinical microbiology and the rational use of antimicrobials.

Upon concluding this editorial cycle, we reaffirm our commitment to scientific rigor, research ethics, and the qualified dissemination of knowledge. The growth of BJHP, reflected both in the volume of publications and in the diversity of its output, is a direct result of the dedicated work of authors, reviewers, associate editors, and the entire editorial team. For the coming year, we plan to expand the journal's international visibility, strengthen institutional partnerships, and encourage submissions that address the contemporary challenges of Pharmacy, Public Health, and Biomedical Sciences. May 2026 be marked by even more advances, scientific collaboration, and social impact.

I am deeply grateful to everyone who contributed to the BJHP throughout 2025. May this new issue inspire reflection and stimulate new research. We continue together, building quality science to promote health.

Prof. Dr. Tiago Marques dos Reis
Editor-in-Chief, Brazilian Journal of Health and Pharmacy